

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajs11623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \*      Welcome to STN International      \* \* \* \* \* \* \* \* \* \*

NEWS 1                Web Page for STN Seminar Schedule - N. America  
NEWS 2 JUL 02 LMEDLINE coverage updated  
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names  
NEWS 4 JUL 02 CHEMCATS accession numbers revised  
NEWS 5 JUL 02 CA/Capplus enhanced with utility model patents from China  
NEWS 6 JUL 16 CAplus enhanced with French and German abstracts  
NEWS 7 JUL 18 CA/Capplus patent coverage enhanced  
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification  
NEWS 9 JUL 30 USGENE now available on STN  
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags  
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition  
NEWS 12 AUG 13 CA/Capplus enhanced with additional kind codes for granted patents  
NEWS 13 AUG 20 CA/Capplus enhanced with CAS indexing in pre-1907 records  
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB  
NEWS 15 AUG 27 USPATOLD now available on STN  
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data  
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index  
NEWS 18 SEP 13 FORIS renamed to SOFIS  
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency  
NEWS 20 SEP 17 CA/Capplus enhanced with printed CA page images from 1967-1998  
NEWS 21 SEP 17 CAplus coverage extended to include traditional medicine patents  
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 23 OCT 02 CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt  
NEWS 24 OCT 19 BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS            STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN            Welcome Banner and News Items  
NEWS IPC8            For general information regarding STN implementation of IPC

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:05:54 ON 14 NOV 2007

=> b reg  
COST IN U.S. DOLLARS  
SINCE FILE ENTRY TOTAL  
FULL ESTIMATED COST 0.21 SESSION 0.21

FILE 'REGISTRY' ENTERED AT 08:06:07 ON 14 NOV 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 NOV 2007 HIGHEST RN 953361-13-2  
DICTIONARY FILE UPDATES: 13 NOV 2007 HIGHEST RN 953361-13-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Documents and Settings\jlau1\My Documents\10509675 - arthritis\species  
structure.str



chain nodes :  
13 14 15 16 17 18 19 20 21 22 23 24  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12  
chain bonds :  
5-7 10-13 12-24 13-14 13-15 14-22 15-16 15-21 16-17 17-18 18-19 19-20 19-23  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12  
exact/norm bonds :  
15-16 15-21 18-19 19-20 19-23  
exact bonds :

5-7 10-13 12-24 13-14 13-15 14-22 16-17 17-18

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS  
21:CLASS 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam

SAMPLE SEARCH INITIATED 08:06:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 sss full

FULL SEARCH INITIATED 08:06:41 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> logoff hold  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
172.10	172.31

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 08:06:55 ON 14 NOV 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajsl1623


PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'REGISTRY' AT 08:55:38 ON 14 NOV 2007  
FILE 'REGISTRY' ENTERED AT 08:55:38 ON 14 NOV 2007  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
172.10	172.31

=>  
Uploading C:\Documents and Settings\jlaul\My Documents\10509675 - arthritis\flurbiprofen  
exact.str




chain nodes :  
13 14 15 16 17 18  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12  
chain bonds :  
5-7 10-13 12-18 13-14 13-17 14-15 14-16  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12  
exact/norm bonds :  
14-15 14-16  
exact bonds :  
5-7 10-13 12-18 13-14 13-17  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L4 STRUCTURE UPLOADED

=> d 14  
L4 HAS NO ANSWERS  
L4 STR




Structure attributes must be viewed using STN Express query preparation.

=> s 14 exact sam  
SAMPLE SEARCH INITIATED 08:56:41 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE  
  
100.0% PROCESSED 8 ITERATIONS 1 ANSWERS  
SEARCH TIME: 00.00.01  
  
FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 8 TO 329  
PROJECTED ANSWERS: 1 TO 80

L5 1 SEA EXA SAM L4

=> d 15 scan

L5 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro- $\alpha$ -methyl-  
MF C15 H13 F O2  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	173.00	173.21

FILE 'CAPLUS' ENTERED AT 08:57:03 ON 14 NOV 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Nov 2007 VOL 147 ISS 21  
FILE LAST UPDATED: 13 Nov 2007 (20071113/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s 15
L6      2879 L5

=> s 16 and py<=2003
      23955884 PY<=2003
L7      2138 L6 AND PY<=2003

=> s 17 and nitroso
      29844 NITROSO
      16 NITROSOS
      29849 NITROSO
      (NITROSO OR NITROSOS)
L8      3 L7 AND NITROSO

=> d 18 scan

L8      3 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
IC      ICM A61K031-54
      ICS C07D513-00; C07D513-02; C07D513-04
CC      1-7 (Pharmacology)
      Section cross-reference(s): 25, 27, 28, 63
TI      Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
ST      NO substituted NSAID prepn antiinflammatory analgesic; antipyretic NO substituted NSAID prepn; gastrointestinal disorder NO substituted NSAID prepn; toxicity NSAID prevention NO substituted NSAID
IT      Analgesics
      Antipyretics
      Toxicity
      (NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)
IT      Thiols (organic), biological studies
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
```

(*S-nitroso*; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Digestive tract  
(disease, lesion; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Amino acids, biological studies  
Aromatic hydrocarbons, biological studies  
Carbohydrates, biological studies  
Hydrocarbons, biological studies  
Oligonucleotides  
Proteins, specific or class  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydroxynitrosohydrazine-containing; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Cytokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Anti-inflammatory agents  
(nonsteroidal; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Nitrates, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(thio-; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT Digestive tract  
Kidney  
(toxicity; NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT 53-86-1, Indomethacin 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen  
RL: ADV (Adverse effect, including toxicity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
(NO-substituted nonsteroidal antiinflammatory compound preparation for compns. and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)

IT 50-33-9, Phenylbutazone, biological studies 50-78-2, Acetylsalicylic acid 54-21-7, Sodium salicylate 58-15-1, Aminopyrine 60-80-0, Antipyrine 61-68-7, Mefenamic acid 62-44-2, Phenacetin 65-45-2, Salicylamide 68-89-3, Dipyrrone 69-72-7D, Salicylic acid, derivs. 89-57-6, Mesalamine 103-82-2D, Phenylacetic acid, derivs. 103-90-2, Acetaminophen 119-36-8, Methyl salicylate 120-72-9D, Indole, derivs. 123-30-8D, p-Aminophenol, derivs. 129-20-4, Oxyphenbutazone 142-29-0D, Cyclopentene, diaryl derivs. 530-78-9, Flufenamic acid 552-94-3, Salsalate 599-79-1, Sulfasalazine 644-62-2, Meclofenamic acid 2016-36-6, Choline salicylate, biological studies 5104-49-4, Flurbiprofen 7048-08-0, Sodium thiosalicylate 12766-00-6D, Quinazolinone, derivs. 13539-59-8, Apazone 13710-19-5, Tolfenamic acid 15307-86-5, Diclofenac 18917-89-0, Magnesium salicylate 21256-18-8, Oxaprozin 22494-42-4, Diflunisal 22760-18-5, Proquazone 26171-23-3, Tolmetin 29679-58-1, Fenoprofen 30544-47-9, Etofenamate 31793-07-4, Pirprofen 31842-01-0, Indoprofen 33005-95-7, Tiaprofenic acid 34552-84-6, Isoxicam 36322-90-4, Piroxicam 36330-85-5, Fenbufen 38194-50-2, Sulindac 39455-90-8D, Pyrazolone, derivs. 41340-25-4, Etodolac 42924-53-8, Nabumetone 55843-86-2, Miroprofen 59804-37-4, Tenoxicam 80937-31-1, CGP 28238 88149-94-4, DuP 697 120210-48-2, Tenidap 123653-11-2, NS-398 158205-05-1, L-745337 158959-32-1, 162054-19-5, SC-58125

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (NO-substituted nonsteroidal antiinflammatory compound preparation for compns.  
 and methods to prevent toxicity induced by nonsteroidal  
 antiinflammatory drugs)

IT 6316-86-5P 6709-70-2P 57564-91-7P 184473-91-4P 184473-93-6P  
 184473-96-9P 184474-00-8P 184474-06-4P 184474-10-0P 184474-14-4P  
 184474-18-8P 184474-22-4P 184474-26-8P 184474-30-4P 184474-36-0P  
 184474-38-2P 184474-40-6P 184474-42-8P 184474-46-2P 184474-48-4P  
 184474-50-8P 184474-54-2P 184474-58-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (NO-substituted nonsteroidal antiinflammatory compound preparation for compns.  
 and methods to prevent toxicity induced by nonsteroidal  
 antiinflammatory drugs)

IT 10102-43-9, Nitrogen monoxide, biological studies 14452-93-8,  
 Nitrosonium 155557-95-2D, derivs.  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (NO-substituted nonsteroidal antiinflammatory compound preparation for compns.  
 and methods to prevent toxicity induced by nonsteroidal  
 antiinflammatory drugs)

IT 39391-18-9, Cyclooxygenase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; NO-substituted nonsteroidal antiinflammatory compound preparation  
 for compns. and methods to prevent toxicity induced by nonsteroidal  
 antiinflammatory drugs)

IT 17071-62-4P 17768-28-4P 51091-84-0P 59512-44-6P 70458-50-3P  
 89031-83-4P 90466-78-7P, 5-Acetoxyisophthalic acid 184473-92-5P  
 184473-94-7P 184473-98-1P 184474-04-2P 184474-07-5P 184474-12-2P  
 184474-16-6P 184474-20-2P 184474-24-6P 184474-29-1P 184474-32-6P  
 184474-33-7P 184474-34-8P 184474-35-9P 184474-37-1P 184474-39-3P  
 184474-41-7P 184474-43-9P 184474-45-1P 184474-47-3P 184474-49-5P  
 184474-51-9P 184474-52-0P 184474-53-1P 184474-55-3P 184474-56-4P  
 184474-57-5P 184474-59-7P 184474-60-0P 184474-61-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and reaction; NO-substituted nonsteroidal antiinflammatory  
 compound preparation for compns. and methods to prevent toxicity induced by  
 nonsteroidal antiinflammatory drugs)

IT 57-88-5, Cholesterol, reactions 79-37-8, Oxalyl chloride 107-88-0,  
 1,3-Butanediol 108-24-7, Acetic anhydride 108-30-5, reactions  
 110-63-4, 1,4-Butanediol, reactions 121-91-5, 1,3-Benzenedicarboxylic  
 acid, reactions 540-80-7, tert-Butyl nitrite 589-29-7,  
 1,4-Benzenedimethanol 928-51-8, 4-Chloro-1-butanol 1462-10-8,  
 2-Methyl-2,5-pentanediol 3262-72-4 3695-77-0, Triphenylmethyl  
 mercaptan 7632-00-0, Sodium nitrite 10387-40-3, Potassium thioacetate  
 10544-72-6, Dinitrogen tetroxide 14635-75-7, Nitrosonium  
 tetrafluoroborate 18162-48-6, tert-Butyldimethylsilyl chloride  
 24785-71-5 26159-34-2 32047-53-3 34300-94-2, 3-Mercapto-3-  
 methylbutanol 39269-10-8, 1,3-Adamantanedicarboxylic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction; NO-substituted nonsteroidal antiinflammatory compound preparation  
 for compns. and methods to prevent toxicity induced by nonsteroidal  
 antiinflammatory drugs)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):  
 HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d 18 and arthritis  
 'AND' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'  
 'ARTHRITIS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB

ALL ----- BIB, AB, IND, RE  
 APPS ----- AI, PRAI  
 BIB ----- AN, plus Bibliographic Data and PI table (default)  
 CAN ----- List of CA abstract numbers without answer numbers  
 CBIB ----- AN, plus Compressed Bibliographic Data  
 CLASS ----- IPC, NCL, ECLA, FTERM  
 DALL ----- ALL, delimited (end of each field identified)  
 DMAX ----- MAX, delimited for post-processing  
 FAM ----- AN, PI and PRAI in table, plus Patent Family data  
 FBIB ----- AN, BIB, plus Patent FAM  
 IND ----- Indexing data  
 IPC ----- International Patent Classifications  
 MAX ----- ALL, plus Patent FAM, RE  
 PATS ----- PI, SO  
 SAM ----- CC, SX, TI, ST, IT  
 SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
           SCAN must be entered on the same line as the DISPLAY,  
           e.g., D SCAN or DISPLAY SCAN)  
 STD ----- BIB, CLASS  
  
 IABS ----- ABS, indented with text labels  
 IALL ----- ALL, indented with text labels  
 IBIB ----- BIB, indented with text labels  
 IMAX ----- MAX, indented with text labels  
 ISTD ----- STD, indented with text labels  
  
 OBIB ----- AN, plus Bibliographic Data (original)  
 OIBIB ----- OBIB, indented with text labels  
  
 SBIB ----- BIB, no citations  
 SIBIB ----- IBIB, no citations  
  
 HIT ----- Fields containing hit terms  
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
                   containing hit terms  
 HITRN ----- HIT RN and its text modification  
 HITSTR ----- HIT RN, its text modification, its CA index name, and  
                   its structure diagram  
 HITSEQ ----- HIT RN, its text modification, its CA index name, its  
                   structure diagram, plus NTE and SEQ fields  
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
                   its structure diagram  
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
                   structure diagram, plus NTE and SEQ fields  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):end

```
=> s 18 and arthritis
      49311 ARTHRITIS
      2 ARTHRITISES
      49311 ARTHRITIS
          (ARTHRITIS OR ARTHRITISES)
L9          0 L8 AND ARTHRITIS
```

=> d 18 1-3 ibib abs

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2000:259972 CAPLUS  
DOCUMENT NUMBER: 132:293042  
TITLE: Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles  
INVENTOR(S): Van Lengerich, Bernhard H.  
PATENT ASSIGNEE(S): General Mills, Inc., USA  
SOURCE: PCT Int. Appl., 56 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021504	A1	20000420	WO 1999-US20905	19991006 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 7201923	B1	20070410	US 1999-233443	19990120
CA 2345815	A1	20000420	CA 1999-2345815	19991006 <--
AU 9963872	A	20000501	AU 1999-63872	19991006 <--
AU 777977	B2	20041104		
EP 1119345	A1	20010801	EP 1999-951433	19991006 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002527375	T	20020827	JP 2000-575480	19991006 <--
PRIORITY APPLN. INFO.:			US 1998-103700P	P 19981009
			US 1998-109696P	P 19981124
			US 1999-233443	A 19990120
			WO 1999-US20905	W 19991006

AB A liquid encapsulant component which contains an active, sensitive encapsulant, such as a live microorganism or an enzyme dissolved or dispersed in a liquid plasticizer is admixed with a plasticizable matrix material. The matrix material is plasticizable by the liquid plasticizer and the encapsulation of the active encapsulant is accomplished at a low temperature and under low shear conditions. The active component is encapsulated and/or embedded in the plasticizable matrix component or material in a continuous process to produce discrete, solid particles. The liquid content of the liquid encapsulant component provides substantially all or completely all of the liquid plasticizer needed to plasticize the matrix component to obtain a formable, extrudable, cuttable, mixture or dough. Removal of liquid plasticizer prior to extrusion is not needed to adjust the viscosity of the mixture for formability. Release of an active component from the matrix may be delayed or controlled over time so that the active component is delivered when and where it is needed to perform its intended function. Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1999:404846 CAPLUS  
DOCUMENT NUMBER: 131:39763  
TITLE: The use of nitric oxide generators for the treatment

of dry eye disorders  
 INVENTOR(S): Gamache, Daniel A.; Miller, Steven T.; Yanni, John M.  
 PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA  
 SOURCE: PCT Int. Appl., 16 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9930716	A1	19990624	WO 1998-US23806	19981110 <--
W: AU, BR, CA, JP, MX, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9913889	A	19990705	AU 1999-13889	19981110 <--
PRIORITY APPLN. INFO.:			US 1997-69711P	P 19971216
			WO 1998-US23806	W 19981110

AB Compns. containing a nitric oxide generator (NOG) and methods of use for treating dry eye are disclosed. The compds. of the invention promote NO production when administered to the eye. It is believed that NO stimulates mucin production in human conjunctival epithelium and are therefore believed to be useful in treating dry eye. A further requirement of a NOG of the invention is that it stimulates mucin production and/or secretion of the conjunctival epithelium and/or ocular goblet cells following topical ocular application. Examples of NOGs include nitroglycerin, sodium nitroprusside, spermine NONOate, (+/-)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide (FK-409), 1-hydroxy-2-oxo-3-(N-methyl-3-aminopropyl)-3-methyl-1-triazene (NOC-7), S-nitrosoglutathione, 4-phenyl-3-furoxancarbonitrile, S-*nitroso*-N-acetyl-penicillamine (SNAP), isosorbide dinitrate, GEA 3268, GEA 5145, GEA 3175, glyceryl trinitrate, molsidomine, 3-morpholinosydnonimine (SIN-1), hydroxylamine, linsidomine, NOC-18, CHF-2363, pirsidomine, N,N'-dimethylhexanediamine (DMHD/NO), 2,2-diethyl-1-*nitroso*-oxyhydrazine (DEA/NO), Et 2NN(O)NONa, NO-ketoprofen, NO-diclofenac, NO-flurbiprofen. The most preferred NOG of the invention is molsidomine.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1996:756296 CAPLUS  
 DOCUMENT NUMBER: 126:14758  
 TITLE: Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs  
 INVENTOR(S): Garvey, David S.; Letts, L. Gordon; Renfroe, H. Burt; Tam, Sang W.  
 PATENT ASSIGNEE(S): Nitromed, Inc., USA; Garvey, David S.; Letts, L. Gordon; Renfroe, H. Burt; Tam, Sang W.  
 SOURCE: PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9632946	A1	19961024	WO 1996-US4931	19960411 <--
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6051588	A	20000418	US 1995-425090	19950419 <--
US 5703073	A	19971230	US 1995-543208	19951013 <--
AU 9654493	A	19961107	AU 1996-54493	19960411 <--
AU 710951	B2	19990930		
EP 821589	A1	19980204	EP 1996-911685	19960411 <--

R: CH, DE, FR, GB, IT, LI, SE			
JP 11509519	T 19990824	JP 1996-531797	19960411 <--
US 6043232	A 20000328	US 1999-235802	19990122 <--
US 6143734	A 20001107	US 2000-495251	20000131 <--
AU 773374	B2 20040520	AU 2001-91447	20011121
PRIORITY APPLN. INFO.:		US 1995-425090	A 19950419
		US 1995-543208	A 19951013
		WO 1996-US4931	W 19960411
		US 1997-899238	A3 19970723
		US 1999-235802	A1 19990122
		AU 1999-65551	A3 19991230

OTHER SOURCE(S): MARPAT 126:14758

AB Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compns. comprising: (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compns. are disclosed. The compds. and compns. protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs. Preparation of compds. of the invention is included, as are comparative in vivo analgesic,antiinflammatory, and gastric lesion activities.

=> d his

(FILE 'HOME' ENTERED AT 08:05:54 ON 14 NOV 2007)

FILE 'REGISTRY' ENTERED AT 08:06:07 ON 14 NOV 2007

L1	STRUCTURE UPLOADED
L2	0 S L1 SSS SAM
L3	0 S L1 SSS FULL
L4	STRUCTURE UPLOADED
L5	1 S L4 EXACT SAM


FILE 'CAPLUS' ENTERED AT 08:57:03 ON 14 NOV 2007

L6	2879 S L5
L7	2138 S L6 AND PY<=2003
L8	3 S L7 AND NITROSO
L9	0 S L8 AND ARTHRITIS

=> d 11


L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> d 14
L4 HAS NO ANSWERS
L4          STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> log off hold
SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:58:53 ON 14 NOV 2007
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajsl1623

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 09:03:02 ON 14 NOV 2007  
FILE 'CAPLUS' ENTERED AT 09:03:02 ON 14 NOV 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.93	189.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

=> b registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.93	189.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

FILE 'REGISTRY' ENTERED AT 09:03:12 ON 14 NOV 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 NOV 2007 HIGHEST RN 953361-13-2  
DICTIONARY FILE UPDATES: 13 NOV 2007 HIGHEST RN 953361-13-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 08:05:54 ON 14 NOV 2007)

FILE 'REGISTRY' ENTERED AT 08:06:07 ON 14 NOV 2007

L1	STRUCTURE UPLOADED
L2	0 S L1 SSS SAM
L3	0 S L1 SSS FULL
L4	STRUCTURE UPLOADED
L5	1 S L4 EXACT SAM


FILE 'CAPLUS' ENTERED AT 08:57:03 ON 14 NOV 2007

L6	2879 S L5
L7	2138 S L6 AND PY<=2003
L8	3 S L7 AND NITROSO
L9	0 S L8 AND ARTHRITIS

FILE 'REGISTRY' ENTERED AT 09:03:12 ON 14 NOV 2007

=> d 15

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 5104-49-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro- $\alpha$ -methyl- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 4-Biphenylacetic acid, 2-fluoro- $\alpha$ -methyl- (8CI)  
CN Hydratropic acid, 3-fluoro-4-phenyl- (7CI)  
OTHER NAMES:  
CN (+)-Flurbiprofen  
CN 2-(2-Fluoro-1,1'-biphenyl-4-yl)propanoic acid  
CN 2-(2-Fluoro-4-biphenyl)propionic acid  
CN 2-(2-Fluoro-4-biphenyl)propanoic acid  
CN 2-(2-Fluoro-4-biphenyl)propionic acid  
CN 2-Fluoro- $\alpha$ -methyl-4-biphenylacetic acid  
CN 2-Fluoro- $\alpha$ -methyl-4-diphenylacetic acid  
CN 3-Fluoro-4-phenylhydratropic acid  
CN Adfeed  
CN Ansaid  
CN Antadys  
CN BTS 18322  
CN Cebutid  
CN dl-2-(2-Fluoro-4-biphenyl)propionic acid  
CN dl-Flurbiprofen  
CN Flugalin  
CN Flurbiprofen  
CN Flurofen  
CN FP 70  
CN FP-A  
CN Froben  
CN rac-Flurbiprofen  
CN Racemic flurbiprofen  
CN Stayban  
CN U 27182  
CN Zepolas  
DR 51543-38-5, 79212-68-3  
MF C15 H13 F O2  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS,  
BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,  
CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB,  
IFIPAT, IFIUDB, IMSCOSEARCH, IMSPATENTS, IPA, MEDLINE, MRCK\*, MSDS-OHS,  
PHAR, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH, SPECINFO, SYNTHLINE,  
TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD, VETU  
(\*File contains numerically searchable property data)  
Other Sources: DSL\*\*, EINECS\*\*, WHO  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2863 REFERENCES IN FILE CA (1907 TO DATE)  
113 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
2879 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.85	191.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 09:04:07 ON 14 NOV 2007